Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test
Executive Summary
Lundbeck’s 5-HT6 antagonist idalopirdine failed its first Phase III test, but as Axovant awaits data from its Phase III study for a competing Alzheimer’s therapy, it’s still unclear whether the entire drug class is doomed to the same fate.
You may also be interested in...
Denovo Dusts Down Lundbeck's Failed Alzheimer's Drug
The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.
Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?
Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.
Revamped Lundbeck Ups Outlook Amid Strong Brintellix and Rexulti Sales
The rebounding Danish CNS specialist raised its 2016 revenue and profit forecasts as it continued to benefit from an ongoing structuring and buoyant sales in the US market, notably for its drugs Brintellix and Rexulti.